Navigation Links
Mixed Results Seen With 'Off-Label' Use of Antipsychotics

TUESDAY, Sept. 27 (HealthDay News) -- Even though off-label use of atypical antipsychotic drugs is common, a new review finds that such use is only effective in a few conditions and can be harmful in others.

Also known as "second-generation" antipsychotics, these drugs are approved in the United States for treatment of schizophrenia, bipolar disorder and depression. But off-label use -- or use not approved by the U.S. Food and Drug Administration -- of these drugs to treat a number of other conditions is growing.

Researchers analyzed findings from 393 clinical studies to gauge effectiveness and uncover harmful side effects when Risperdal, Zyprexa, Seroquel, Abilify, Geodon, Saphris, Fanapt and Invega were used outside of FDA-approved indications.

Off-label use included treatment for behavioral symptoms in dementia, anxiety, depression, obsessive-compulsive disorder, eating disorders, post-traumatic stress disorder, insomnia, personality disorders and substance abuse.

The investigators found that Abilify (aripiprazole), Zyprexa (olanzapine) and Risperdal (risperidone) were associated with small but statistically significant benefits for elderly people with dementia symptoms, such as aggression, psychosis and mood changes.

Seroquel (quetiapine) was 26 percent more effective than placebo in people with generalized anxiety disorder, and Risperdal was four times more effective than placebo in people with obsessive-compulsive disorder.

There was no evidence that atypical antipsychotics benefited people with substance abuse or eating disorders, according to Dr. Alicia Ruelaz Maher, of RAND Health in Santa Monica, Calif., and colleagues.

The researchers also found that certain atypical antipsychotics increased the risk of death, stroke, movement disorders and urinary tract symptoms in elderly patients. In younger patients, some of the drugs caused problems such as weight gain, fatigue, sedation, and akathisia, also known as restless leg syndrome.

The study is published in the Sept. 28 issue of the Journal of the American Medical Association.

"The benefits and harms vary among atypical antipsychotic medications for off-label use," the researchers concluded in a journal news release. "This evidence should prove useful for clinicians considering off-label prescribing of atypical antipsychotic medications, and should contribute to optimal treatment decision making for individual patients with specific clinical symptoms and unique risk profiles."

More information

The U.S. National Institute of Mental Health has more about mental health medications.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, Sept. 27, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Bone drug is mixed blessing for breast cancer patients
2. Trials of Type 1 Diabetes Vaccines Bring Mixed Results
3. Models Photos May Spur Mixed Messages About Body Image
4. Americas Health a Mixed Bag: Report
5. Elder law expert: Health care reform act a mixed bag for seniors
6. Antibiotics a Mixed Bag for Kids Ear Infections: Analysis
7. U.S. Report on Kids Health Brings Mixed Results
8. Extending lifespan has mixed effects on learning and memory
9. Company stock prices before public announcements of oncology trial results
10. Check Plastic Surgeons Credentials or Risk Tragic Results, Experts Warn
11. Parents anxiety about newborn screening results does not lead to increased health care use
Post Your Comments:
Related Image:
Mixed Results Seen With 'Off-Label' Use of Antipsychotics
(Date:11/30/2015)... ... November 30, 2015 , ... The recently published 32nd ... System (NPDS) reveals that in 2014, someone called a poison center about every ... of which were human exposure cases. , The American Association of Poison Control ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... promoting breast and prostate cancer education and prevention—is joining forces with the award-winning ... philanthropy and Hollywood elegance on December 7, 2015 at the Union League of ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as ... more so for a child’s exposure limits. , The original Nov 2015 CR ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., ... womb. "My last baby had high blood pressure due to loud noises," she said, ... their babies from noise pollution as well as radio waves and microwaves." , The ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... automated breast density assessment and enterprise analytics solutions, here at the 101st ... (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015  PTS Diagnostics, the U.S.-based manufacturer ... analyzers, A1CNow ® systems, and PTS Detect™ ... of patents that will propel the company into the ... Europe . The technology is a ... those on smartphones and tablets, and uses test strip ...
(Date:11/30/2015)... , Nov. 30, 2015 Oramed Pharmaceuticals ... focused on the development of oral drug delivery systems, ... agreements valued at up to $50,000,000 with Hefei Tianhui Incubator of Technologies ... oral insulin capsule, ORMD-0801, in China ... Macau . The agreements were signed at ...
(Date:11/30/2015)... , Nov. 30, 2015 Cumberland Pharmaceuticals (CPIX), today ... live at on December 3, 2015. TIME: ... TIME: 3:15p.m. ET LINK: --> ... --> ... where investors are invited to ask the company questions in ...
Breaking Medicine Technology: